Vertex Pharma (VRTX) Tops Q1 EPS by 16c, Revenues Beat; Affirms FY19 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Vertex Pharma (VRTX) Tops Q1 EPS by 16c, Revenues Beat; Affirms FY19 Revenue Guidance Below Consensus

Vertex Pharma (VRTX) Announces FDA Approval of KALYDECO as First CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age

April 30, 2019 8:31 AM EDT

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages six months to less than 12 months who have at least one mutation in their cystic fibrosis transmembrane... More